PTSM: Pharmaceutical Technology Sourcing and Management
Pharmaceutical Technology's podcast series from CPhI.
Patricia Van Arnum, senior editor of Pharmaceutical Technology, discusses strategies in optimizing API syntheses and manufacturing. Participants include Jan-Olav Henck, PhD, chief scientific officer at Aptuit, Fred Fleitz, senior manager of process R&D with Cambridge Major Laboratories, and Roger McDonald, director of business development with Cambridge Major Laboratories. Also, Annemieke Timmers, CPhI brand director with UBM, discusses CPhI Worldwide, which was held in Frankfurt in October 2011 and other CPhI events.
Listen here to a podcast with Jan-Olav Henck, PhD, chief scientific officer at Aptuit, who discusses strategies and considerations in polymorph screening.
Listen here to a podcast with Fred Fleitz, senior manager, process R&D with Cambridge Major Laboratories, and Roger McDonald, director of business development with Cambridge Major Laboratories, discuss recent project work in optimizing several API syntheses. Fleitz discusses the approach taken in a condensation reaction between a naphthoquinone derivative and a substituted methyl vinyl ketone. McDonald discusses the optimization of a synthetic route for a complex natural product analogue. In another project, he discusses an approach taken to maintain the desired enantioselectivity of a molecule containing a chiral cyclopropane moiety during scale-up.
Listen here to a podcast with Annemieke Timmers, CPhI brand director with UBM, discusses CPhI Worldwide, which was held in Frankfurt in October 2011, and other CPhI events.
Clinical Supply Planning in Europe - Balancing Cost, Flexibility and Time
December 19th 2024The packaging and distribution of clinical supplies is a fundamental piece to the overall success of a clinical trial, and advance preparation can help establish a more efficient supply chain. Selecting the best geographical location for those activities, however, depends on the clinical trial protocol, business decisions, and even the investigational medicinal product (IMP) being studied.